Table 1 Baseline characteristics
From: Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure
ALL ( n = 218) | High-dose group ( n = 117) | Low-dose group ( n = 101) | P value | |
|---|---|---|---|---|
Baseline Characteristics | ||||
Gender, n (%), male | 153 (70.2) | 85 (72.6) | 68 (67.3) | 0.392 |
Age, median (IQR), years | 49 (38–60) | 46 (29–55) | 54 (44–62) | < 0.001 |
BMI, median (IQR), kg/m2 | 27.7 (24.2–30.9) | 26.2 (22.5–29.4) | 29.1 (26.0–33.2) | < 0.001 |
SAPS II (IQR) | 47 (37–56) | 46 (36–57) | 47 (37–55) | 0.871 |
SOFA Score (IQR) | 9 (8–10) | 9 (7–10) | 9 (8–10) | 0.650 |
Respiration-sub-score | 4 | 4 | 4 | |
Coagulation-sub-score | 0 (0–1) | 0 (0–1) | 0 (0–2) | 0.573 |
Liver-sub-score | 0 (0–1) | 0 (0–2) | 0 (0–1) | 0.059 |
Cardiovascular-sub-score | 4 (3–4) | 4 (3–4) | 4 (3–4) | 0.151 |
Renal-sub-score | 1 (0–4) | 1 (0–4) | 1 (0–2) | 0.004 |
RESP-Score (IQR) | 1 (-2–3)) | 1 (-1–3) | 0 (-2–3) | 0.002 |
Sepsis, n (%) | 184 (84.4) | 88 (75.2) | 96 (95.1) | < 0.001 |
Primary ARDS, n (%) | 173 (79.4) | 104 (88.9) | 69 (68.3) | < 0.001 |
Immunocompromised, n (%) | 68 (31.2) | 31 (26.5) | 37 (36.6) | 0.107 |
Liver failure* | 53 (24.3) | 34 (29.1) | 19 (18.8) | 0.079 |
Comorbidities, n (%) | ||||
Diabetes mellitus | 42 (19.4) | 19 (16.4) | 23 (22.8) | 0.234 |
Arterial hypertension | 76 (35.0) | 34 (29.3) | 42 (41.6) | 0.059 |
Coronary artery disease | 21 (9.6) | 7 (6.0) | 14 (13.9) | 0.049 |
Malignancy (solid) | 8 (3.7) | 2 (1.7) | 6 (5.9) | 0.098 |
Malignancy (Hematologic) | 14 (6.4) | 8 (6.8) | 6 (5.9) | 0.788 |